MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
2.070
-0.030
-1.43%
Opening 09:45 01/08 EST
OPEN
2.120
PREV CLOSE
2.100
HIGH
2.120
LOW
2.070
VOLUME
5.18K
TURNOVER
--
52 WEEK HIGH
51.75
52 WEEK LOW
1.650
MARKET CAP
6.47M
P/E (TTM)
-0.0821
1D
5D
1M
3M
1Y
5Y
1D
Silexion outlines 2026 plans after transformational 2025 progress
TipRanks · 2d ago
Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements
Reuters · 2d ago
Silexion Therapeutics issues letter to shareholders
TipRanks · 2d ago
Silexion Targets Human Trials in 2026 After Strong Progress Against KRAS Cancers
Benzinga · 2d ago
Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers
Reuters · 2d ago
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026
Barchart · 2d ago
Weekly Report: what happened at SLXN last week (1229-0102)?
Weekly Report · 3d ago
Weekly Report: what happened at SLXN last week (1222-1226)?
Weekly Report · 12/29/2025 10:16
More
About SLXN
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.